Crewe Advisors LLC Trims Stock Position in Danaher Co. (NYSE:DHR)

Crewe Advisors LLC cut its position in shares of Danaher Co. (NYSE:DHR) by 30.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 413 shares of the conglomerate’s stock after selling 177 shares during the quarter. Crewe Advisors LLC’s holdings in Danaher were worth $95,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Choreo LLC increased its stake in Danaher by 4.4% during the fourth quarter. Choreo LLC now owns 21,703 shares of the conglomerate’s stock worth $4,984,000 after acquiring an additional 911 shares during the last quarter. Tectonic Advisors LLC increased its stake in Danaher by 7.6% during the fourth quarter. Tectonic Advisors LLC now owns 3,350 shares of the conglomerate’s stock worth $769,000 after acquiring an additional 238 shares during the last quarter. Nvwm LLC increased its stake in Danaher by 1.6% during the fourth quarter. Nvwm LLC now owns 5,592 shares of the conglomerate’s stock worth $1,284,000 after acquiring an additional 89 shares during the last quarter. Confluence Wealth Services Inc. grew its stake in shares of Danaher by 4.3% in the fourth quarter. Confluence Wealth Services Inc. now owns 2,904 shares of the conglomerate’s stock valued at $713,000 after buying an additional 120 shares in the last quarter. Finally, Osprey Private Wealth LLC grew its stake in shares of Danaher by 1.1% in the fourth quarter. Osprey Private Wealth LLC now owns 11,250 shares of the conglomerate’s stock valued at $2,582,000 after buying an additional 125 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Down 1.0 %

Shares of NYSE DHR opened at $209.95 on Friday. The company has a market cap of $151.64 billion, a price-to-earnings ratio of 39.76, a price-to-earnings-growth ratio of 2.80 and a beta of 0.83. Danaher Co. has a 12-month low of $209.10 and a 12-month high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock’s 50 day simple moving average is $233.96 and its 200 day simple moving average is $252.39.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the business posted $2.09 EPS. Equities research analysts expect that Danaher Co. will post 7.77 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.51%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.45%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on DHR shares. Wells Fargo & Company lowered their target price on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Scotiabank started coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. Robert W. Baird lowered their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Finally, Guggenheim started coverage on Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.